Avadel Pharmaceuticals (AVDL) Liabilities and Shareholders Equity (2016 - 2022)
Historic Liabilities and Shareholders Equity for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to $145.8 million.
- Avadel Pharmaceuticals' Liabilities and Shareholders Equity fell 4480.72% to $145.8 million in Q3 2022 from the same period last year, while for Dec 2022 it was $524.8 million, marking a year-over-year decrease of 5171.32%. This contributed to the annual value of $247.3 million for FY2021, which is 2065.61% down from last year.
- Latest data reveals that Avadel Pharmaceuticals reported Liabilities and Shareholders Equity of $145.8 million as of Q3 2022, which was down 4480.72% from $157.9 million recorded in Q2 2022.
- In the past 5 years, Avadel Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $351.9 million in Q1 2018 and a low of $145.8 million during Q3 2022
- Its 5-year average for Liabilities and Shareholders Equity is $239.6 million, with a median of $247.3 million in 2021.
- In the last 5 years, Avadel Pharmaceuticals' Liabilities and Shareholders Equity tumbled by 5065.61% in 2019 and then soared by 11017.33% in 2020.
- Quarter analysis of 5 years shows Avadel Pharmaceuticals' Liabilities and Shareholders Equity stood at $190.3 million in 2018, then fell by 20.42% to $151.4 million in 2019, then soared by 105.79% to $311.6 million in 2020, then decreased by 20.66% to $247.3 million in 2021, then crashed by 41.05% to $145.8 million in 2022.
- Its Liabilities and Shareholders Equity stands at $145.8 million for Q3 2022, versus $157.9 million for Q2 2022 and $221.1 million for Q1 2022.